The study ended early because the protector cap needle-free injector (PCNFI)
failed to prevent contamination in the first batch tested (8.2% failure
Vaccine. 2008 Mar
4;26(10):1344-52. Epub 2008 Jan 18.
Preventing contamination between injections with multiple-use
nozzle needle-free injectors: a safety trial.
PATH, 1455 NW Leary Way, Seattle, WA
98107, USA. email@example.com
Multiple-use nozzle jet injectors (MUNJIs), a type of needle-free injector, use
a high-pressure stream to penetrate skin and deliver medicament. Concerns for
their potential to transmit blood borne pathogens led to development of a hybrid
MUNJI for use in mass immunizations. The HSI-500, referred to here as a
protector cap needle-free injector (PCNFI), utilizes a disposable cap as a
shield between the reusable injector nozzle and the skin to reduce the risk of
contamination. This study aimed to determine the presence of hepatitis B virus
(HBV) contamination in post-injection ("next person") samples immediately
following injection in HBV-carrier adults. Tolerability and pain were also
assessed. The study ended early because the PCNFI failed to prevent
contamination in the first batch tested (8.2% failure rate). The
injections were very well tolerated, with most followed by no bleeding (81.2%)
or mild bleeding (7.8%). 55.2% of participants experienced no pain while 42.3%
experienced mild pain following injection.
PMID: 18272265 [PubMed - indexed for